Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

(2013) Paolo A Ascierto et al.   LANCET ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

(2011) Sneha V. Gupta et al.   AAPS Journal

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12

(2009) Frédéric Thuaud et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One